Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida , Gainesville, FL, USA.
Expert Opin Drug Metab Toxicol. 2020 Oct;16(10):953-964. doi: 10.1080/17425255.2020.1803279. Epub 2020 Sep 9.
β-blockers are among the most widely prescribed of all drugs, used for treatment of a large number of cardiovascular diseases. Herein we evaluate literature pertaining to pharmacogenetics of β-blocker therapy, provide insight into the robustness of the genetic associations, and determine the appropriateness for translating these genetic associations into clinical practice.
A literature search was conducted using PubMed to collate evidence on associations between , and genetic variation and drug-response outcomes in the presence of β-blocker exposure. Pharmacokinetic, pharmacodynamic, and clinical outcomes studies were included if genotype data and β-blocker exposure were documented.
Substantial data suggest that specific and genotypes are associated with improved β-blocker efficacy and have potential for use to guide therapy decisions in the clinical setting. While the data do not justify ordering a pharmacogenetic test, if genotype is available in the electronic health record, there may be clinical utility for understanding dosing of β-blockers.
β受体阻滞剂是目前应用最广泛的药物之一，被广泛用于治疗多种心血管疾病。本文评估了β受体阻滞剂治疗的药物遗传学相关文献，深入了解了遗传相关性的稳健性，并确定了将这些遗传相关性转化为临床实践的适宜性。
使用 PubMed 进行文献检索，以收集关于β受体阻滞剂暴露情况下，β受体阻滞剂药物反应结局与 基因和 基因变异之间关联的证据。如果记录了基因型数据和β受体阻滞剂暴露情况，则纳入药代动力学、药效动力学和临床结局研究。
大量数据表明，特定的 基因型和 基因型与改善β受体阻滞剂疗效相关，并且有可能用于指导临床环境中的治疗决策。虽然这些数据不足以支持进行药物遗传学检测，但如果电子健康记录中存在 基因型，则了解β受体阻滞剂的剂量可能具有临床意义。
